Swiss biopharmaceutical company ObsEva SA (SIX: OBSN) has announced that it has regained full rights to its pipeline candidate, nolasiban, after the termination of a previous license agreement with China-based Yuyuan Biological Technology.
Nolasiban’s Profile and Its Importance in IVF Treatment
Nolasiban is an oral oxytocin receptor antagonist that plays a crucial role in enhancing clinical pregnancy and live birth rates in women undergoing embryo transfer as part of in-vitro fertilization (IVF) procedures. Originally, ObsEva had acquired global rights to nolasiban from Merck KGaA in a 2013 deal and later sub-licensed exclusive rights to Yuyuan Bioscience for the development and commercialization of the molecule in Greater China, including Hong Kong and Macau, in a January 2020 agreement.
Reclamation of Rights and Future Prospects
With the termination of the agreement with Yuyuan Biological Technology, ObsEva now holds the global rights to nolasiban, which may impact the drug’s development and commercialization strategies moving forward. This move allows ObsEva to reassess and potentially expand its approach to bringing nolasiban to market, particularly in regions where IVF treatments are in high demand.-Fineline Info & Tech
